See more : Bellavista Resources Limited (BVR.AX) Income Statement Analysis – Financial Results
Complete financial analysis of Vapotherm, Inc. (VAPO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Vapotherm, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
- WELL Health Technologies Corp. (WHTCF) Income Statement Analysis – Financial Results
- Up Young Cornerstone Corp. (6728.TWO) Income Statement Analysis – Financial Results
- Tectona Ltd (TECT.TA) Income Statement Analysis – Financial Results
- FarGlory Hotel Co.,Ltd (2712.TW) Income Statement Analysis – Financial Results
- Daiho Corporation (1822.T) Income Statement Analysis – Financial Results
Vapotherm, Inc. (VAPO)
About Vapotherm, Inc.
Vapotherm, Inc., a medical technology company, focuses on the development and commercialization of proprietary high velocity therapy products used to treat patients of various ages suffering from respiratory distress in the United States and internationally. The company offers precision flow systems, such as Precision Flow Hi-VNI, Precision Flow Plus, Precision Flow Classic, and Precision Flow Heliox that deliver heated, humidified, and oxygenated air at a high velocity to patients through a small-bore nasal interface. It also provides companion products, including Vapotherm Transfer Unit, which allows patients to be transferred between care areas within the hospital or ambulate while on therapy; Q50 compressor, which provides compressed air necessary to run the precision flow systems; aerosol aeroneb adaptor to facilitate delivery of ultrasonic aerosolized medication; aerosol disposable patient circuit that is designed to streamline the provision of continuous and intermittent delivery of aerosol medication; and tracheostomy adaptors. In addition, Vapotherm, Inc. offers ProSoft cannula to provide gentle contact with the skin; and disposable products comprising single-use disposables and nasal interfaces, as well as Oxygen Assist Modules, which helps clinicians maintain oxygen levels within a target range. The company sells its products to hospitals. Vapotherm, Inc. was founded in 1993 and is headquartered in Exeter, New Hampshire.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 68.67M | 66.80M | 113.29M | 125.73M | 48.10M | 42.38M | 35.60M | 30.12M |
| Cost of Revenue | 40.39M | 49.56M | 60.10M | 62.69M | 26.79M | 25.61M | 22.36M | 20.18M |
| Gross Profit | 28.28M | 17.24M | 53.19M | 63.05M | 21.31M | 16.77M | 13.24M | 9.94M |
| Gross Profit Ratio | 41.19% | 25.81% | 46.95% | 50.14% | 44.30% | 39.58% | 37.19% | 33.00% |
| Research & Development | 14.21M | 20.80M | 18.41M | 16.96M | 13.38M | 8.77M | 7.57M | 6.21M |
| General & Administrative | 19.26M | 27.80M | 31.38M | 24.04M | 18.41M | 11.19M | 8.02M | 5.94M |
| Selling & Marketing | 32.55M | 46.09M | 60.14M | 65.07M | 37.69M | 33.93M | 26.22M | 20.03M |
| SG&A | 51.81M | 73.89M | 91.52M | 89.10M | 56.10M | 45.11M | 34.24M | 25.97M |
| Other Expenses | 0.00 | 0.00 | 18.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 66.03M | 94.69M | 109.93M | 106.06M | 69.48M | 53.88M | 41.81M | 32.18M |
| Cost & Expenses | 106.41M | 144.25M | 170.03M | 168.75M | 96.27M | 79.49M | 64.17M | 52.36M |
| Interest Income | 78.00K | 139.00K | 91.00K | 257.00K | 860.00K | 118.00K | 3.00K | 8.00K |
| Interest Expense | 18.73M | 11.64M | 2.60M | 4.71M | 5.10M | 3.06M | 2.23M | 716.00K |
| Depreciation & Amortization | 4.98M | 5.18M | 5.65M | 4.77M | 3.08M | 2.17M | 1.53M | 1.34M |
| EBITDA | -34.36M | -100.39M | -52.40M | -43.01M | -44.89M | -37.23M | -27.24M | -20.89M |
| EBITDA Ratio | -47.60% | -107.97% | -45.00% | -30.21% | -91.94% | -82.18% | -75.94% | -69.36% |
| Operating Income | -39.08M | -77.45M | -56.74M | -43.01M | -48.16M | -37.23M | -28.87M | -22.22M |
| Operating Income Ratio | -56.91% | -115.94% | -50.08% | -34.21% | -100.12% | -87.86% | -81.11% | -73.78% |
| Total Other Income/Expenses | -18.99M | -12.86M | -2.71M | -8.49M | -3.04M | -5.24M | -2.44M | -849.00K |
| Income Before Tax | -58.07M | -113.25M | -59.88M | -51.50M | -51.21M | -42.47M | -31.01M | -23.07M |
| Income Before Tax Ratio | -84.56% | -169.53% | -52.85% | -40.96% | -106.45% | -100.21% | -87.10% | -76.60% |
| Income Tax Expense | 126.00K | 11.00K | -76.00K | 4.71M | -146.00K | 2.41M | 206.00K | 127.00K |
| Net Income | -58.19M | -113.26M | -59.80M | -56.21M | -51.06M | -42.47M | -31.01M | -23.07M |
| Net Income Ratio | -84.74% | -169.55% | -52.78% | -44.71% | -106.14% | -100.21% | -87.10% | -76.60% |
| EPS | -9.64 | -33.89 | -18.48 | -18.88 | -21.96 | -116.95 | -357.12 | -394.95 |
| EPS Diluted | -9.64 | -33.89 | -18.44 | -18.88 | -21.96 | -116.95 | -357.12 | -394.95 |
| Weighted Avg Shares Out | 6.04M | 3.34M | 3.24M | 2.98M | 2.33M | 363.14K | 86.82K | 58.42K |
| Weighted Avg Shares Out (Dil) | 6.04M | 3.34M | 3.24M | 2.98M | 2.33M | 363.14K | 86.82K | 58.42K |
Vapotherm to Report Third Quarter 2021 Financial Results
Vapotherm Raises Annual Sales Outlook Amid Surge In COVID-19 Cases
FDA Gives 510(K) Nod To Vapotherm's Next-Gen High-Velocity Therapy
Vapotherm Announces FDA 510(k) Clearance for HVT 2.0 Next Generation Platform
Vapotherm, Inc. (VAPO) CEO Joe Army on Q2 2021 Results - Earnings Call Transcript
Vapotherm (VAPO) Reports Q2 Loss, Tops Revenue Estimates
Vapotherm to Report Second Quarter 2021 Financial Results
Vapotherm to Report Second Quarter 2021 Financial Results
Vapotherm: Hardly Breathing Room
Vapotherm to Host First Investor Day
Source: https://incomestatements.info
Category: Stock Reports